The Effect of Chronic Activation of the Novel Endocannabinoid Receptor GPR18 on Myocardial Function and Blood Pressure in Conscious Rats.
Although acute activation of the novel endocannabinoid receptor GPR18 causes hypotension, there are no reports on GPR18 expression in the heart or its chronic modulation of cardiovascular function. In this study, after demonstrating GPR18 expression in the heart, we show that chronic (2 weeks) GPR18 activation with its agonist abnormal cannabidiol (abn-cbd; 100 µg·kg·d; i.p) produced hypotension, suppressed the cardiac sympathetic dominance, and improved left ventricular (LV) function (increased the contractility index dp/dtmax and reduced LV end-diastolic pressure, LVEDP) in conscious rats. Ex vivo studies revealed increased: (1) cardiac and plasma adiponectin (ADN) levels; (2) vascular (aortic) endothelial nitric oxide synthase (eNOS) expression, (3) vascular and serum nitric oxide (NO) levels; (4) myocardial and plasma cyclic guanosine monophosphate (cGMP) levels; (5) phosphorylation of myocardial protein kinase B (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) along with reduced myocardial reactive oxygen species (ROS) in abn-cbd treated rats. These biochemical responses contributed to the hemodynamic responses and were GPR18-mediated because concurrent treatment with the competitive GPR18 antagonist (O-1918) abrogated the abn-cbd-evoked hemodynamic and biochemical responses. The current findings present new evidence for a salutary cardiovascular role for GPR18, mediated, at least partly, via elevation in the levels of adiponectin.
*Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, NC; and †Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, Egypt.
Asmaa I
AI
Matouk
Ashraf
A
Taye
Mohamed A
MA
El-Moselhy
Gehan H
GH
Heeba
Abdel A
AA
Abdel-Rahman
D000818:Animals; D000840:Anisoles / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D003243:Consciousness / Q000187:drug effects / Q000502:physiology*; D003510:Cyclohexanes / Q000494:pharmacology; D008297:Male; D009206:Myocardium; D051381:Rats; D017208:Rats, Wistar; D043882:Receptors, Cannabinoid / Q000378:metabolism*; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology*
C552735:1,3-dimethoxy-5-methyl-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)benzene; D000840:Anisoles; D003510:Cyclohexanes; C588261:GPR18 protein, rat; D043882:Receptors, Cannabinoid
Br J Pharmacol. 2014 Aug;171(16):3908-17
24762058
J Biol Chem. 2003 Nov 14;278(46):46188-94
12952947
Diabet Med. 2012 Jan;29(1):80-7
22082489
Cardiovasc Diabetol. 2012 Aug 08;11:94
22873349
Circulation. 2011 Sep 13;124(11 Suppl):S55-61
21911819
Environ Health Perspect. 1978 Oct;26:193-206
363416
J Am Coll Cardiol. 1989 Nov 1;14(5):1139-48
2681319
Food Chem Toxicol. 2012 Feb;50(2):116-23
22019695
PeerJ. 2016 Mar 21;4:e1835
27018161
Med Res Rev. 2001 Jan;21(1):1-60
11135298
Br J Pharmacol. 2010 Jun;160(3):594-603
20136843
Mol Pharmacol. 2003 Mar;63(3):699-705
12606780
Obesity (Silver Spring). 2009 Feb;17 (2):262-8
19057532
Br J Pharmacol. 2007 Nov;152(5):825-31
17704827
J Appl Physiol (1985). 2006 Mar;100(3):1011-8
16293701
Circulation. 2013 Jun 4;127(22):2209-21
23625959
J Clin Invest. 2000 Aug;106(4):493-9
10953024
Genomics. 1997 Jun 15;42(3):462-6
9205118
Br J Pharmacol. 2007 Dec;152(7):1092-101
17876302
J Pharmacol Exp Ther. 2014 Apr;349(1):29-38
24431468
Biol Reprod. 2009 Sep;81(3):595-604
19474061
J Pharmacol Exp Ther. 2014 Oct;351(1):44-53
25100751
Alcohol Clin Exp Res. 2014 May;38(5):1205-15
24754626
Br J Pharmacol. 2003 Apr;138(7):1320-32
12711633
Pharmacol Res Perspect. 2015 Jun;3(3):e00143
26236485
Nutr Res. 2013 May;33(5):397-405
23684441
Am J Physiol Endocrinol Metab. 2014 Apr 1;306(7):E740-7
24368668
Pharmacol Rev. 2010 Dec;62(4):588-631
21079038
Circulation. 2007 Mar 20;115(11):1408-16
17339545
Cell Growth Differ. 2001 Aug;12(8):397-408
11504705
PLoS One. 2015 Sep 18;10(9):e0138463
26384023
Mol Nutr Food Res. 2016 Jan;60(1):92-102
26337420
Circ Res. 1989 Jul;65(1):1-21
2544316
J Pharmacol Exp Ther. 2007 Jun;321(3):930-7
17379772
Trends Pharmacol Sci. 2009 Mar;30(3):156-63
19233486
Circulation. 1996 Mar 1;93(5):1043-65
8598068
Br J Pharmacol. 2013 Jun;169(4):834-43
23461720
FEBS Lett. 2005 Sep 26;579(23):5163-9
16140297
J Pharmacol Exp Ther. 2005 Sep;314(3):1328-37
15937146
BMC Neurosci. 2010 Mar 26;11:44
20346144
Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2409-16
16415076
Biochem Biophys Res Commun. 2006 Sep 1;347(3):827-32
16844083
Mol Pharmacol. 2013 Jan;83(1):267-82
23104136
J Pharmacol Exp Ther. 2012 Aug;342(2):461-71
22580349
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14136-41
10570211
Biochem Biophys Res Commun. 2005 Jun 24;332(1):200-5
15896318
Pharmacol Ther. 2015 Feb;146:61-93
25242198
Am J Cardiol. 2016 Feb 15;117(4):574-9
26800774
Am J Physiol. 1971 May;220(5):1249-55
5574640
Circulation. 2000 Feb 15;101(6):660-7
10673259